4 recruiting, 2 terminated, 1 completed, 1 withdrawn. 4 Phase 4, 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 4 | Recruiting 3, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 2 | Terminated 2 |
Follow Staphylococcus Aureus Endocarditis: new trials by email Literature Review of Staphylococcus Aureus Endocarditis trials Research Report on Staphylococcus Aureus Endocarditis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia Clopidogrel, Aspirin - Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia | Phase 4 | Recruiting | Todd C. Lee MD MPH FIDSA | 300 | 2026-02-23 | 2026-11-12 |
| Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia Dabigatran, Apixaban, edoxaban - Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia | Phase 4 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 300 | 2026-01-15 | 2026-09-24 |
| Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus Rifampin, No rifampin - Staphylococcus Aureus Endocarditis, Prosthetic Valve Endocarditis | Phase 3 | Terminated | Todd C. Lee MD MPH FIDSA | 1 | 2025-11-10 | 2026-09-21 |
| Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia Daptomycin for Injection, Vancomycin (IV) - Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia | Phase 4 | Recruiting | Todd C. Lee MD MPH FIDSA | 300 | 2024-11-14 | 2026-09-09 |
| Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia Ertapenem, Placebo - Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia | Phase 2 | Recruiting | Todd C. Lee MD MPH FIDSA | 60 | 2024-05-20 | 2026-11-02 |
| Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase Exebacase, Placebo - Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis | Phase 3 | Terminated | ContraFect | 259 | 2019-12-20 | 2023-11-02 |
| Oritavancin for Staphylococcus Aureus Infections in Opioid Users Oritavancin Injection - Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis | Phase 4 | Withdrawn | University of Pennsylvania | 2019-07-01 | 2022-04-06 | |
| Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia CF-301, Placebo - Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis | Phase 2 | Completed | ContraFect | 121 | 2017-05-23 | 2021-10-08 |
Bacteremia (2) · Staphylococcal Infections (2)
Bacterial Infections (2) · Bacterial Infections and Mycoses (2) · Gram-Positive Bacterial Infections (2) · Infections (2) · Inflammation (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Sepsis (2) · Systemic Inflammatory Response Syndrome (2)
exebacase (2) · Aspirin (1) · Clopidogrel (1) · Dabigatran (1) · Daptomycin (1) · Ertapenem (1) · Injections (1) · Rifampin (1) · Rivaroxaban (1) · Vancomycin (1) · apixaban (1) · edoxaban (1) · oritavancin (1)
Todd C. Lee MD MPH FIDSA (4) · ContraFect (2) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · University of Pennsylvania (1)
Canada (5) · United States (3) · Australia (1) · Belgium (1) · Bulgaria (1) · Chile (1) · Czechia (1) · France (1) · Germany (1) · Greece (1) · Guatemala (1) · Israel (1) · Italy (1) · New Zealand (1) · Russia (1)
Todd C Lee, MD MPH FIDSA (3) · Emily G McDonald, MD MSc (2) · Emily G McDonald, MD MSC (1) · Matthew P Cheng, MD (1) · Pablo Tebas, MD (1)
PMID 32271718, PMID 33910968, PMID 38297916, PMID 41387009, PMID 41433510
2025 (4)